{
  "pmcid": "12344096",
  "sha256": "0ef56d16c364b9695aa209e6015ac0c440adca05a396d605b181b7ee54532abb",
  "timestamp_utc": "2025-11-09T23:33:42.927192+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.37521185635569,
    "reading_ease": 32.305238457153735,
    "word_count": 277
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Synthetic Angiotensin-II in Severe Burn Injury"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence with allocation concealment via sealed envelopes."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were adults with severe burn injury requiring vasoactive support. Eligibility criteria included age over 18 and burn injury covering more than 20% of total body surface area."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention group received synthetic AT-II, while the control group received standard catecholamine-based therapy."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the efficacy and safety of synthetic angiotensin-II (AT-II) compared to standard catecholamine-based therapy in acute burn shock resuscitation and septic shock in burn patients."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was mean arterial pressure (MAP) improvement within 24 hours."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence with allocation concealment via sealed envelopes."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was applied to outcome assessors."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomised: 100 to the AT-II group and 100 to the control group, between January 2020 and June 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was conducted on 98 participants in the AT-II group and 97 in the control group using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The AT-II group showed a significant improvement in MAP (mean difference = 5.2 mm Hg, 95% CI 3.1 to 7.3; p = 0.01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were reported in 3% of the AT-II group and 1% of the control group, primarily mild gastrointestinal side-effects."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678"
      },
      "Funding": {
        "score": 1,
        "evidence": "This trial was funded by the National Institutes of Health."
      }
    },
    "total_score": 23,
    "max_score": 25
  }
}